– Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 –
Read more at newswire.caProvided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.